Investors Purchase High Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) saw unusually large options trading on Wednesday. Stock investors acquired 33,531 call options on the company. This is an increase of 180% compared to the average volume of 11,957 call options.

Recursion Pharmaceuticals Stock Performance

RXRX traded up $0.04 during midday trading on Thursday, reaching $7.53. The company had a trading volume of 16,494,409 shares, compared to its average volume of 16,561,031. Recursion Pharmaceuticals has a 12-month low of $5.60 and a 12-month high of $15.74. The business has a 50-day moving average price of $6.88 and a two-hundred day moving average price of $6.95. The stock has a market cap of $2.94 billion, a PE ratio of -4.92 and a beta of 0.85. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The firm had revenue of $26.08 million during the quarter, compared to analysts' expectations of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals's revenue for the quarter was up 147.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.43) EPS. On average, sell-side analysts expect that Recursion Pharmaceuticals will post -1.56 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on RXRX. Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 11th. KeyCorp cut their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 8th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of "Hold" and a consensus price target of $8.75.

Insider Transactions at Recursion Pharmaceuticals

In related news, CFO Michael Secora sold 15,000 shares of the stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the sale, the chief financial officer now directly owns 1,499,631 shares of the company's stock, valued at approximately $11,487,173.46. This represents a 0.99 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $6.72, for a total transaction of $76,923.84. Following the transaction, the director now directly owns 7,077,560 shares in the company, valued at $47,561,203.20. This represents a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 37,894 shares of company stock valued at $279,279 over the last ninety days. 15.75% of the stock is owned by company insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Axxcess Wealth Management LLC boosted its stake in Recursion Pharmaceuticals by 4.3% in the 3rd quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company's stock worth $289,000 after purchasing an additional 1,795 shares during the period. Green Alpha Advisors LLC boosted its position in shares of Recursion Pharmaceuticals by 2.9% in the third quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company's stock valued at $427,000 after acquiring an additional 1,800 shares during the period. Wedmont Private Capital grew its stake in Recursion Pharmaceuticals by 10.6% during the fourth quarter. Wedmont Private Capital now owns 20,943 shares of the company's stock valued at $144,000 after acquiring an additional 2,000 shares in the last quarter. Amalgamated Bank increased its holdings in Recursion Pharmaceuticals by 52.4% during the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company's stock worth $54,000 after acquiring an additional 2,459 shares during the period. Finally, Victory Capital Management Inc. lifted its stake in Recursion Pharmaceuticals by 13.5% in the 2nd quarter. Victory Capital Management Inc. now owns 21,891 shares of the company's stock worth $164,000 after purchasing an additional 2,598 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.